| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 12/07/2005 | CN1230156C Fibrauretine dispersant tablet and its preparing method |
| 12/07/2005 | CN1230155C Stretchable patch |
| 12/07/2005 | CN1230154C Sustained release compositions and a method of preparing pharmaceutical compositions |
| 12/07/2005 | CN1230153C Film Coated tablet compositions having enhanced disintegration characteristics |
| 12/07/2005 | CN1230152C Hydrogel particle formulations |
| 12/07/2005 | CN1230151C Non-invasive transdermal vaccination |
| 12/07/2005 | CN1230150C Slow release pharmaceutical compositions comprising lithium carbonate |
| 12/07/2005 | CN1230141C Improved stability for injection solutions |
| 12/07/2005 | CN1230087C Method and apparatus for coating centers |
| 12/07/2005 | CA2509183A1 Topical anesthetic preparation for pretreatment for upper gastrointestinal endoscopy |
| 12/07/2005 | CA2469339A1 Sustained release propafenone hydrochloride capsules |
| 12/07/2005 | CA2469327A1 Propafenone hydrochloride capsules containing microtablets |
| 12/06/2005 | USRE38912 for treating a number of complaints, particularly respiratory diseases |
| 12/06/2005 | US6972321 Monomeric protein of the TGF-β family |
| 12/06/2005 | US6972300 Compounds and compositions for delivering active agents |
| 12/06/2005 | US6972282 Process for producing a product containing antihypertensive tripeptides |
| 12/06/2005 | US6972194 culturing cells in envelopes comprising acrylic amide homopolymers, for use in immunization against tumor cells and prophylaxis of diabetes; vaccines |
| 12/06/2005 | US6972132 Tablets or capsules comprising drugs such as cystine, encapsulated disintegration layer comprising chitosan; preferential drug delivery to intestines |
| 12/06/2005 | US6972130 mixtures of crystal structured hydroxyapatite, drugs and/or biological cells, having biocompatibility and bioresorption, for use in drug delivery |
| 12/06/2005 | US6972128 allogeneic immunotherapy; vaccines; immortalization |
| 12/06/2005 | US6972127 administering an effective dose of a polypeptide comprising an immunogenic fragment of A beta (SEQ ID NO:1) and an adjuvant in a regime effective to induce an immune response comprising antibodies to the A beta fragment; Alzheimer's disease |
| 12/06/2005 | CA2303537C Solid oral dosage form comprising a combination of metformin and glibenclamide |
| 12/06/2005 | CA2303177C Taste masked pharmaceutical compositions |
| 12/06/2005 | CA2193248C Caplet and gelatin covering therefor |
| 12/06/2005 | CA2180846C Method of treating disorders of the eye |
| 12/06/2005 | CA2172053C Process (i) for the preparation of powdered medicament |
| 12/06/2005 | CA2129527C Pharmaceutical composition usable as an analgesic, comprising (r)-(benzoyl-3-phenyl)-2-propionic acid |
| 12/06/2005 | CA2079831C Biodegradable polymer composition |
| 12/04/2005 | CA2568914A1 Therapeutic agents, and methods of making and using the same |
| 12/04/2005 | CA2509185A1 Immediate release dosage form comprising shell having openings therein |
| 12/02/2005 | CA2509077A1 Water-based compositions comprising a polyethylene glycol-based solubilizing agent and a taxane useful in the treatment of coronary artery disease |
| 12/01/2005 | WO2005113608A1 Method of covalently linking hyaluronan and chitosan |
| 12/01/2005 | WO2005113384A1 Fluid product dispenser |
| 12/01/2005 | WO2005113236A2 Films comprising a liquid-absorbant inner layer, an antimicrobial material and an impermeable outer layer |
| 12/01/2005 | WO2005113128A1 Compositions containing a hollow glucan particle or a cell wall particle encapsulating a terpene component, methods of making and using them |
| 12/01/2005 | WO2005113030A1 Tissue closing preparation |
| 12/01/2005 | WO2005113010A1 Surface-modified and solubility-improved hard capsule |
| 12/01/2005 | WO2005113009A1 Solid pharmaceutical formulation |
| 12/01/2005 | WO2005113007A2 Powders containing novel oligosaccharide mixtures and methods for producing the same |
| 12/01/2005 | WO2005113005A2 Transcutaneous and/or transdermal transport of materials |
| 12/01/2005 | WO2005113002A1 Ophthalmic percutaneously absorbed preparation containing muscarinic receptor agonist |
| 12/01/2005 | WO2005112996A1 1,4 o-linked saccharose derivatives for stabilizing antibodies or antibody derivatives |
| 12/01/2005 | WO2005112984A2 Apparatus and method for transdermal delivery of parathyroid hormone agents |
| 12/01/2005 | WO2005112977A2 Compositions for treatment with glucagon-like peptide, and methods of making and using the same |
| 12/01/2005 | WO2005112957A1 Treatment of lung diseases and pre-lung disease conditions |
| 12/01/2005 | WO2005112947A2 Use of atp for the manufacture of a medicament for the prevention and treatment of oxidative stress and related conditions |
| 12/01/2005 | WO2005112909A1 Anti-inflammatory analgesic external aqueous liquid preparation |
| 12/01/2005 | WO2005112902A2 Medicinal aerosol formulation products with improved chemical stability |
| 12/01/2005 | WO2005112901A1 Novel extended release composition of venlafaxine hydrochloride containing polyvinyl acetate |
| 12/01/2005 | WO2005112900A1 Pharmaceutical tablets comprising two or more unitary segments |
| 12/01/2005 | WO2005112899A2 Methods and systems for providing an interface between an ambulatory medical device and a display device |
| 12/01/2005 | WO2005112898A1 Pharmaceutical tablets having a relatively inactive segment |
| 12/01/2005 | WO2005112897A2 Immediate release pharmaceutical tablets with height greater than width |
| 12/01/2005 | WO2005112896A2 Dosage form for delivery of multiple drug forms |
| 12/01/2005 | WO2005112895A2 Ingestible device platform for the colon |
| 12/01/2005 | WO2005112894A1 Nucleic acid microspheres, production and delivery thereof |
| 12/01/2005 | WO2005112893A1 Microspheres comprising protein and showing injectability at high concentrations of said agent |
| 12/01/2005 | WO2005112892A1 Spray-dried powders containing at least one 1,4 o-linked saccharose derivative and methods for producing the same |
| 12/01/2005 | WO2005112891A2 Encapsulated transfer factor compositions and methods of use |
| 12/01/2005 | WO2005112890A1 Liposome and method of preparing the same |
| 12/01/2005 | WO2005112889A2 Transmucosal delivery formulations |
| 12/01/2005 | WO2005112888A2 Methods for making injectable polymer hydrogels |
| 12/01/2005 | WO2005112887A2 Composition comprising intercalated functional-active organic compounds |
| 12/01/2005 | WO2005112886A2 Methods and articles for the delivery of therapeutic agents |
| 12/01/2005 | WO2005112885A2 Oligonucleotide-containing microspheres, their use for the manufacture of a medicament for treating diabetes type 1 |
| 12/01/2005 | WO2005112884A1 Intravitreal implants comprising microspheres which encapsulate a tyrosine kinase inhibitor and a biodegradable polymer |
| 12/01/2005 | WO2005112883A1 Preserved pharmaceutical compositions comprising cyclodextrins |
| 12/01/2005 | WO2005112882A2 Pharmaceutical compositions |
| 12/01/2005 | WO2005112881A1 The dispersible montmorillonite tablet and its preparation technology |
| 12/01/2005 | WO2005112870A1 Pharmaceutical tablets having a separation mark positioned on the side of said tablets |
| 12/01/2005 | WO2005112654A2 Compositions comprising edible oils and vitamins and/or minerals and methods for making the compositions |
| 12/01/2005 | WO2005112569A2 Methods for compounding and delivering a therapeutic agent to the adventitia of a vessel |
| 12/01/2005 | WO2005112564A2 Germline and sequence variants of humanized antibodies and methods of making and using them |
| 12/01/2005 | WO2005112546A2 Mucinous glycoprotein (muc-1) vaccine |
| 12/01/2005 | WO2005092310A3 Chemically stable compositions of 4-hydroxy tamoxifen |
| 12/01/2005 | WO2005079387A3 Implantable drug delivery device including wire filaments |
| 12/01/2005 | WO2005074888A3 Replacement enzyme cochleates |
| 12/01/2005 | WO2005065721A3 Use of an anti-inflammatory compound for the reduction of inflammation secondary to the administration of a lipid-nucleic acid complex |
| 12/01/2005 | WO2005063203A3 Multiparticulate formulations for oral delivery |
| 12/01/2005 | WO2005053650A8 Azithromycin dosage forms with reduced side effects |
| 12/01/2005 | WO2005053638A3 Composition and delivery system |
| 12/01/2005 | WO2005044225A3 Process for production of essentially solvent-free small particles |
| 12/01/2005 | WO2005041934A3 Pharmaceutical agent-containing formulation comprising a coating |
| 12/01/2005 | WO2005027976A3 Composition comprising ether lipid |
| 12/01/2005 | WO2005023215A3 Particles shaped as platelets |
| 12/01/2005 | WO2005011642A9 Single unit pharmaceutical composition comprising a mixture of a fibrate and an homocysteine reducing agent |
| 12/01/2005 | WO2004096118B1 Composition for improving cognition and memory |
| 12/01/2005 | WO2004071384A3 New pharmaceutical compositions based on anticholinergics and tace-inhibitors |
| 12/01/2005 | WO2004045585A9 Media milling using nonspherical grinding media |
| 12/01/2005 | WO2004037289A3 Novel injectable depot formulations |
| 12/01/2005 | WO2004026280A3 Granulate formulation of the rapamycin ester cci-779 |
| 12/01/2005 | US20050267486 Methods and compositions usable in cataract surgery |
| 12/01/2005 | US20050267341 Optical sampling interface system for in vivo measurement of tissue |
| 12/01/2005 | US20050267280 Lactone bearing absorbable polymers |
| 12/01/2005 | US20050267233 Anti-microbial handle system |
| 12/01/2005 | US20050267222 Stabilized composition |
| 12/01/2005 | US20050267217 Methods and devices for preventing transmission of sexually transmitted diseases |
| 12/01/2005 | US20050267209 urea and isomorphs consisting of phenylalanine, tyrosine, cinnamic acid, hippuric acid, procaine, resveratrol, tryptophan, 5-fluorouracil and uracil; bioavailability |
| 12/01/2005 | US20050267201 Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same |
| 12/01/2005 | US20050267198 Novel processes for preparing amorphous atorvastatin hemi-calcium |